On November 20, 2018 Medigene AG (FSE: MDG1, Prime Standard, SDAX) reported its participation at the following upcoming investor and scientific conferences (Press release, MediGene, NOV 20, 2018, View Source [SID1234531493]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bryan Garnier Healthcare Conference
Date: 22 – 23 November 2018
Location: Paris, France

45th ISOBM Congress (International Society of Oncology & BioMarkers)
Date: 24 – 27 November 2018
Location: Hamburg

German Equity Forum
Date: 26 – 28 November 2018
Location: Frankfurt, Germany
Dr Kai Pinkernell, CMO and CDO of Medigene AG, will give a company presentation on 26 November at 5 pm.

American Society for Hematology (ASH) (Free ASH Whitepaper) Annual Meeting
Date: 1 – 4 December 2018
Location: San Diego, USA
In addition to Medigene participating at the conference, Medigene’s partner Oslo University Hospital will present a poster on their compassionate use data of five AML patients receiving their DC vaccines partially using Medigene’s DC vaccine technologies (December 2, 2018, 6:00 PM – 8:00 PM in Hall GH). To view the abstract of the poster entitled "Immune Monitoring of Vaccine Quality and Persistence of Specific T Cell Responses in Five AML Patients Receiving Extended Dendritic Cell Vaccination Under Compassionate Use"" please visit: ash.confex.com/ash/2018/webprogram/Paper114557.html

Cell Therapy Manufacturing & Gene Therapy Congress
Date: 4 – 6 December 2018
Location: Amsterdam, The Netherlands